These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38691847)

  • 1. Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
    Moure CJ; Vara B; Cheng MM; Sondey C; Muise E; Park E; Vela Ramirez JE; Su D; D'Souza S; Yan Q; Yeung CS; Zhang M; Mansueto MS; Linn D; Buchanan M; Foti R; DiMauro E; Long B; Simov V; Barry ER
    Mol Cancer Ther; 2024 Aug; 23(8):1095-1108. PubMed ID: 38691847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
    Kulkarni A; Mohan V; Tang TT; Post L; Chan YC; Manning M; Thio N; Parker BL; Dawson MA; Rosenbluh J; Vissers JH; Harvey KF
    EMBO Rep; 2024 Sep; 25(9):3944-3969. PubMed ID: 39103676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
    Graham K; Lienau P; Bader B; Prechtl S; Naujoks J; Lesche R; Weiske J; Kuehnlenz J; Brzezinka K; Potze L; Zanconato F; Nicke B; Montebaur A; Bone W; Golfier S; Kaulfuss S; Kopitz C; Pilari S; Steuber H; Hayat S; Kamburov A; Steffen A; Schlicker A; Buchgraber P; Braeuer N; Font NA; Heinrich T; Kuhnke L; Nowak-Reppel K; Stresemann C; Steigemann P; Walter AO; Blotta S; Ocker M; Lakner A; von Nussbaum F; Mumberg D; Eis K; Piccolo S; Lange M
    Cell Chem Biol; 2024 Jul; 31(7):1247-1263.e16. PubMed ID: 38537632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.
    Kandasamy S; Adhikary G; Rorke EA; Friedberg JS; Mickle MB; Alexander HR; Eckert RL
    Mol Cancer Res; 2020 Mar; 18(3):343-351. PubMed ID: 31732616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
    Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
    Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth.
    Maruyama J; Inami K; Michishita F; Jiang X; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Miyamura N; Hirayama J; Nishina H; Nogawa D; Yamamoto K; Hata Y
    Mol Cancer Res; 2018 Feb; 16(2):197-211. PubMed ID: 29061667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction.
    Bum-Erdene K; Zhou D; Gonzalez-Gutierrez G; Ghozayel MK; Si Y; Xu D; Shannon HE; Bailey BJ; Corson TW; Pollok KE; Wells CD; Meroueh SO
    Cell Chem Biol; 2019 Mar; 26(3):378-389.e13. PubMed ID: 30581134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1102-1120. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alantolactone is a natural product that potently inhibits YAP1/TAZ through promotion of reactive oxygen species accumulation.
    Nakatani K; Maehama T; Nishio M; Otani J; Yamaguchi K; Fukumoto M; Hikasa H; Hagiwara S; Nishina H; Mak TW; Honma T; Kondoh Y; Osada H; Yoshida M; Suzuki A
    Cancer Sci; 2021 Oct; 112(10):4303-4316. PubMed ID: 34289205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
    He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
    Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
    Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
    J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.
    Yuan Y; Park J; Feng A; Awasthi P; Wang Z; Chen Q; Iglesias-Bartolome R
    Nat Commun; 2020 Mar; 11(1):1472. PubMed ID: 32193376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.